<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bai L</submitter><funding>National Cancer Institute</funding><funding>National Institute on Minority Health and Health Disparities</funding><funding>U.S. Department of Education</funding><pagination>101707</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10248552</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>34</volume><pubmed_abstract>Chemoresistance is a major obstacle in the clinical management of metastatic, castration-resistant prostate cancer (PCa). It is imperative to develop novel strategies to overcome chemoresistance and improve clinical outcomes in patients who have failed chemotherapy. Using a two-tier phenotypic screening platform, we identified bromocriptine mesylate as a potent and selective inhibitor of chemoresistant PCa cells. Bromocriptine effectively induced cell cycle arrest and activated apoptosis in chemoresistant PCa cells but not in chemoresponsive PCa cells. RNA-seq analyses revealed that bromocriptine affected a subset of genes implicated in the regulation of the cell cycle, DNA repair, and cell death. Interestingly, approximately one-third (50/157) of the differentially expressed genes affecte</pubmed_abstract><journal>Translational oncology</journal><pubmed_title>Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models.</pubmed_title><pmcid>PMC10248552</pmcid><funding_grant_id>5U54MD007590</funding_grant_id><funding_grant_id>R01CA256058</funding_grant_id><funding_grant_id>R42CA217491</funding_grant_id><pubmed_authors>White EZ</pubmed_authors><pubmed_authors>Hinton CV</pubmed_authors><pubmed_authors>Li D</pubmed_authors><pubmed_authors>Wu AY</pubmed_authors><pubmed_authors>Du Y</pubmed_authors><pubmed_authors>Wu D</pubmed_authors><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Cook N</pubmed_authors><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Zhao R</pubmed_authors><pubmed_authors>Fu H</pubmed_authors><pubmed_authors>Bai L</pubmed_authors><pubmed_authors>Danaher A</pubmed_authors><pubmed_authors>Bowen NJ</pubmed_authors><pubmed_authors>Kucuk O</pubmed_authors><pubmed_authors>Qui M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models.</name><description>Chemoresistance is a major obstacle in the clinical management of metastatic, castration-resistant prostate cancer (PCa). It is imperative to develop novel strategies to overcome chemoresistance and improve clinical outcomes in patients who have failed chemotherapy. Using a two-tier phenotypic screening platform, we identified bromocriptine mesylate as a potent and selective inhibitor of chemoresistant PCa cells. Bromocriptine effectively induced cell cycle arrest and activated apoptosis in chemoresistant PCa cells but not in chemoresponsive PCa cells. RNA-seq analyses revealed that bromocriptine affected a subset of genes implicated in the regulation of the cell cycle, DNA repair, and cell death. Interestingly, approximately one-third (50/157) of the differentially expressed genes affecte</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jun</publication><modification>2025-04-27T02:19:11.165Z</modification><creation>2025-04-06T18:31:05.09Z</creation></dates><accession>S-EPMC10248552</accession><cross_references><pubmed>37271121</pubmed><doi>10.1016/j.tranon.2023.101707</doi></cross_references></HashMap>